Sientra (NASDAQ:SIEN) issued its quarterly earnings results on Thursday. The medical instruments supplier reported ($0.45) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.02, Briefing.com reports. Sientra had a negative return on equity of 123.80% and a negative net margin of 151.96%. The firm had revenue of $22.41 million for the quarter, compared to analyst estimates of $20.05 million. During the same period in the previous year, the firm earned ($0.72) earnings per share. The company’s revenue was up 32.8% compared to the same quarter last year.
Shares of NASDAQ SIEN traded up $1.84 during midday trading on Friday, hitting $8.84. 5,333,200 shares of the stock traded hands, compared to its average volume of 861,066. Sientra has a one year low of $4.78 and a one year high of $19.38. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.99 and a current ratio of 2.33. The business has a 50 day moving average price of $6.56 and a two-hundred day moving average price of $6.61. The company has a market cap of $351.20 million, a PE ratio of -2.72 and a beta of 0.24.
Several brokerages have issued reports on SIEN. BidaskClub raised Sientra from a “sell” rating to a “hold” rating in a research note on Thursday, October 10th. Craig Hallum decreased their price objective on Sientra from $20.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, July 25th. Zacks Investment Research upgraded Sientra from a “sell” rating to a “hold” rating in a report on Tuesday, November 5th. ValuEngine upgraded Sientra from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Finally, Maxim Group restated a “buy” rating and set a $12.00 price objective (down previously from $16.00) on shares of Sientra in a report on Friday, August 9th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $15.75.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Read More: What is the G-20?
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.